Mantle Cell Lymphoma

Real-world data show zanubrutinib cuts atrial fibrillation, major bleeding, and mortality versus ibrutinib in B‑cell cancers—guiding safer BTK inhibitor choices.

Mosunetuzumab, a bispecific, plus polatuzumab vedotin, an antibody-drug conjugate, deliver high response rates in relapsed MCL, potentially enabling outpatient community oncology treatment and wider patient access.

A new study suggests that incorporating proteomic data can help refine risk stratification in mantle cell lymphoma (MCL).

Adults can undergo CAR T-cell therapy for relapsed or refractory mantle cell lymphoma after the full approval of the treatment.

Dual inhibition of BIRC5 and MCL-1 showed strong synergistic activity in preclinical models of MCL.

The study covers the period of 2015-2019 in Germany, before approvals for CAR T-cell therapy, pirtobrutinib, and the arrival of less toxic BTK inhibitors.

UK real-world data show that bridging therapy before brexu-cel in mantle cell lymphoma boosts responses but also increases cytopenias and early mortality.

Meta-analysis across B-cell lymphomas shows zanubrutinib (Brukinsa) delivers higher ORR/CR than acalabrutinib (Calquence) or ibrutinib among BTK inhibitors.

Investigators in China touted durable responses seen in a phase 2 study of the CAR T-cell therapy relma-cel, which has a similar mechanism of action as liso-cel. At present, there are no approved CAR T-cell therapies for relapsed/refractory mantle cell lymphoma in China.

A review article examines questions about sequencing treatments in light of recent developments in relapsed/refractory mantle cell lymphoma.

An examination of patient outcomes from the ZUMA-2 trial creates new questions about treatment sequencing.

A study from Sweden, the largest of its kind, challenges the standard 24-month milestone as the key point when early relapse is a concern.

Patients with mantle cell lymphoma experience improved quality of life and physical functioning after treatment with pirtobrutinib, a BTK inhibitor.

Patients with mantle cell lymphoma experienced better survival rates when treated at academic centers compared with community facilities.

Frontline zanubrutinib regimens achieved objective response rates of 100% with deep remissions in older patients and younger, high-risk patients with MCL.

Interim GLOVe trial results show that the frontline combination of glofitamab, lenalidomide, and venetoclax induces rapid, deep, and predominantly MRD-negative remissions in high-risk mantle cell lymphoma with manageable toxicity.

A chemotherapy-free, MRD-guided regimen achieved deep, durable remissions in untreated MCL with manageable toxicity and the potential for time-limited therapy.

FDA has granted sonrotoclax priority review for relapsed mantle cell lymphoma, showcasing promising trial results.

Mantle cell lymphoma treatment offers options if patients relapse after CAR T-cell therapy, from bispecific antibodies, antibody drug conjugates, and other emerging therapies.

The tablet formulation of zanubrutinib (Brukinsa; BeOne) is now approved for all 5 indications across several hematological cancers.